:237-42.
20. O’Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufﬁciency
and the risk of lower extremity peripheral arterial disease: results from
the Heart and Estrogen/Progestin Replacement Study (HERS). J Am
Soc Nephrol 2004;15:1046-51.
21. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE,
Ueland PM, et al. Plasma homocysteine as a risk factor for vascular
disease. The European Concerted Action Project. JAMA 1997;277:
1775-81.
22. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl
J Med 1998;338:1042-50.
23. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation
1998;98:731-3.

34S Conte and Pomposelli et al

24. Ridker P, Stampfer MJ, Rifai N. Novel risk factors for atherosclerosis:
a comparison of C-reactive protein, ﬁbrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
25. Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N,
et al. Asymmetric dimethylarginine correlates with measures of
disease severity, major adverse cardiovascular events and all-cause
mortality in patients with peripheral arterial disease. Vasc Med
2010;15:267-74.
26. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY,
et al. Beta2-microglobulin as a biomarker in peripheral arterial disease:
proteomic proﬁling and clinical studies. Circulation